25. March 2021 | Compleo and DISA Elektro AG enter into exclusive cooperation with SAG Schweiz AG
Compleo and DISA Elektro AG enter into exclusive cooperation with SAG Schweiz AG to the archive Headline Exclusive distribution of the Compleo Cito range via the Swiss Automotive Group AG network DC charging solutions for more than 6,000 car dealerships Compleo to support car dealers by offering a holistic consulting concept Dortmund, March 25, 2021 […]
Global ESG Monitor 2021 reveals serious deficits
What are companies doing to ensure human rights along the supply chain? And how do they deal with problems raised by stakeholders? Corporate sustainability reports are supposed to provide answers to these questions. However, the Global ESG Monitor shows that many ESG reports worldwide are not transparent and comprehensive enough yet. For the Global ESG […]
Global Corporate Leaders Leave Investors Blind on ESG
In an elaborate study, cometis together with the market research institute KOHORTEN as well as currie comunications (AU) and Xenophon (US) examined 140 international companies with regard to their sustainability reporting.
March 1, 2021 SMT Scharf AG: FY 2020 operating result prospectively lower than expected
SMT Scharf AG (German Securities Code (WKN) 575198, ISIN DE0005751986) announced that, as part of the preparation of the 2020 consolidated financial statements on the basis of preliminary figures, it has transpired that the operating result (EBIT) for the 2020 fiscal year is expected to amount to EUR -8.1 million (2019: EUR 6.8 million).
March 1, 2021 SMT Scharf AG: Revenue and earnings in 2020 significantly impacted by coronavirus and one-off effects
SMT Scharf AG (WKN 575198, ISIN DE0005751986), one of the world’s leading suppliers of customised transport solutions and logistics systems for underground mining, reports revenue of EUR 50.2 million for the 2020 fiscal year on the basis of preliminary figures (2019: EUR 75.4 million).
EXCiPACT certification for c-LEcta’s high production standards
Leipzig, March 2, 2021 – c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, can significantly reduce the cost of supplier audits for customers thanks to its recent award of EXCiPACT certification. The certificate confirms compliance with particularly high quality standards in production and distribution. For customers from the pharmaceutical industry in particular, these standards are an important criterion for qualifying suppliers and the closure of contracts. The certification significantly eases cooperation with new and existing customers for c-LEcta. EXCiPACT certification is internationally recognized and confirms that c-LEcta complies with “Good Manufacturing Practice” and “Good Distribution Practice” for pharmaceutical excipients.
February 25, 2021 SMT Scharf AG: Revocation of admission to the Regulated Market of the Frankfurt Stock Exchange
SMT Scharf AG (German Securities Code (WKN) 575198, ISIN DE0005751986) has been informed as part of its downlisting from the Frankfurt Stock Exchange that the exchange has today published its decision to revoke the admission of the shares of SMT Scharf AG to trading on its Regulated Market and in its Prime Standard segment.
ESG: The pressure of NGOs on companies
At least since the Fridays for Future demonstrations took place, it seems society is placing increasing importance on the protection of environment, human rights and social justice –fundamental ESG issues. A golden era for NGOs? After all, they’ve been campaigning on these issues for decades – which makes them dangerous for companies as well. NGOs […]
12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million € contribution to sales in 2021
Ad hoc news to the archive Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million € contribution to sales in 2021 Grünwald, February 12, 2021 – Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) expects the cooperation with BioNTech SE, Mainz, in the production of the Covid-19 […]
February 12, 2021 | Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute high double-digit million € in sales in 2021
Corporate news to the archive Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute high double-digit million € in sales in 2021 Grünwald, February 12, 2021 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of off-patent branded pharmaceuticals for selected therapeutic areas, expects the collaboration with BioNTech SE, […]